Madrigal Pharmaceuticals, Inc. (MDGL)
Healthcare · NMS
Price as at 12 Aug 2026, 12:46 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Madrigal Pharmaceuticals, Inc. trades at USD535.27, which is 60% above the USD214.74 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 48 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
MDGL dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
MDGL earnings and analyst estimates
Recommendation mix, 15 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
MDGL passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- John Paulson, PAULSON & CO. INC.$719.52M · 27.9% of book
- Ken Griffin, CITADEL ADVISORS LLC$272.36M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$73.58M · 0.1% of book
- Marshall Wace, MARSHALL WACE, LLP$54.69M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$43.60M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Madrigal Pharmaceuticals, Inc. (MDGL) undervalued?
Against our fair value estimate of USD214.74, MDGL at USD535.27 is 60% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own MDGL?
10 of the institutions we track reported a position in MDGL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its MDGL data?
Fundamentals for MDGL come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 12 Aug 2026, 12:46 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for MDGL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.